Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-371-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- including 14-day recovery period
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Substance type: dark blue powder
- Physical state: solid
- Impurities (identity and concentrations): moisture and water soluble matter < 1 %
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): , 99% pur
- Substance type: dark blue powder
- Physical state: solid
- Analytical purity: 99 %
- Impurities (identity and concentrations): moisture and water soluble matter < 1 %
- Lot/batch No.: 21993
- Storage condition of test material: at ambient temperature or in a cool store
-Degree of chlorination: ca 13 chlorine subsitutents on the rings
-Other identifiers in report: CAS-number and structure
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River UK
- Age at study initiation: ca. 5 weeks
- Weight at study initiation: 101 - 121 g
- Housing: 5 animals of the same sex per cage
- Diet: RMI (E) SQC pelleted diet, ad libitum
- Water: public drinking water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 19 - 25 °C
- Humidity: 40 - 70 %
- Air changes: at least 10 per hr
- Photoperiod: 12hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- maize oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test material was prepared for administration as a series of graded concentrations in maize oil. All formulations were prepared freshly each day and administered within four hours of preparation.
Animals received the test material or vehicle control formulations by gavage at a volume dose of 5 ml/kg bw. All animals were dosed once each day approx. at the same time, seven days per week. The volume administered to each animal was claculated from the body weight measured immediately before each administration.
The formulations were stirred using a magnetic stirrer before and throughout the dosing procedure. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentrations of test substance were determined in formulations prepared for one occasion of dosing during weeks 1 and 4 of treatment.
- Duration of treatment / exposure:
- daily for 28 (animals in the reversibility phase group) or 30 (animals in the main study group) consecutive days.
- Frequency of treatment:
- once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5 animals per sex per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- All animals were treated for at least 28 days. Treatment and the recording of serial observations continued for all main study animals throughout the main study necropsy period (therefore main study animals were treated for 30 days). The reversibility phase commenced on day 29 and lasted for 16 days. The recording of serial observations continued throughout the reversibility necropsy period.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS AND DETAILED CLINICAL OBSERVATIONS: Yes
All animals were observed at least twice daily for evidence of reaction to treatment or ill-health. Individual observations of all animals were also recorded before and after dosing on day of treatment. Additionally, a more detailed weekly exaination was performed on each animal. During acclimatization and recovery period, the animals and their cages were observed at least once daily.
BODY WEIGHT: Yes
Each animal was weighed during the acclimatization period, on the day of treatment and at weekly intervals throughout the treatment and reversibility period and before necropsy.
FOOD CONSUMPTION AND EFFICIENCY :
The weight of food supplied to each cage, the remaining and any an estimate of any spilled was recorded for each week throughout the treatment and reversibility periods. From these records the mean weekly consumption was calculated.
The group mean food conversion efficiencieswere calculated for each week of the treatment and reversibility periods.
HAEMATOLOGY: Yes
On day 30 of treatment (before dosing) blood samples were collected from all main study animals after overnight starvation. All samples were examined for the following characteristics:
Packed cell volume (PCV), hemoglobin concentration (HB), erythrocyte count (RBC), mean cell haemoglobin concentration (MCHC), mean cell haemoglobin (MCH), mean cell volume (MCV), total and differential leukocyte count (WBC), platelet count (PLAT), blood film - Romanowski stain for abnormal morphology and unusual cell types, incl. normoblasts, prothrombin time (PT) and activated partial thromboplastin time (PTTK).
CLINICAL CHEMISTRY: Yes
On day 30 of treatment (before dosing) blood samples were collected from all main study animals after overnight starvation. All samples were examined for the following characteristics:
Alkaline phosphatase activity (ALP), alanine amino-transferase (ALT), aspartate amino-transferase activity (AST), gamma glutamyl transpeptidase activity (GGT), glucose concentration (GLUC), total bilirubin concentration (BILT), total cholesterol concentration (CHOL), total glyceride concentration (TRIG), creatinine concentration (CREA), urea concentration, total protein concentration (TP), electrophoretic protein fractions (ALB, A-1, A-2, BETA, GAMMA), albumin-globulin ratio (A/G), sodium (Na), potassium (K), chloride (Cl), calcium (Ca), inorganic phosphate (Phos).
On day 16 of the recovery period, blood samples were obtained after overnight starvation and the samples were examined for ALT (males and females) and urea concentration (males only).
URINALYSIS: Yes
On day 30 of treatment, overnight urine samples were collected from all main study animals. Animals were deprived from water from approx. 12:30 hand placed into an invividual metabolism cage (at approx. 17 h) without food or water. Urine was collected until approx. 9:00 h the following day. Samples were examined for appearance (APP), volume (VOL), pH, specific gravity (SG), protein (PROT), glucose (GLUC), ketones (KET), bilirubin (BIL) and blood. Sediment from centrifugation was examined for epithelial cells (EP), polymorphonuclear leucocytes (P), erythrocytes (RBC), crystals (CRY), spermatozoa and precursors (S) or other abnormalities (A).
- Sacrifice and pathology:
- All animals were killed by carbon dioxide inhalation.
GROSS- and HISTOPATHOLOGY: Yes
All animals were subjected to a detailled necropsy, including a review of the history of each animal and a detailled examination of the external features and orifices, the neck and associated tissues and the cranial, thoracic, abdominal and pelvic cavities and their viscera. The requisite organs were weighed, external and cut surfaces of organs and tissues were examined as appropriate. Abnormalities and interactions were noted and the required tissue samples preserved in fixative.
The following organs were taken and the weights were recorded: adrenals, brain, epididymides, heart, kidneys, liver, ovaries, prostate, seminal vesicles, spleen, testes.
Adrenals, heart, kidneys, liver, spleen and testes were preserved for histopathology.
The following organs were preserved, but not processed histologically: Thoratic aorta, brain, bronchi, caecum, colon, duodenum, epididymides, eyes and optic nerves, harderian glands, ileum, jejunum, lachrymal glands, lungs, lymph nodes - mandibular and mesenteric, mammary glands - caudal and cranial, oesophagus, ovaries, pancreas, pituitary, prostate, rectum, submandibular salivary glands, sciatic nerves, seminal vesicles, sceletal muscle - thigh, skin, spinal cord, sternum, stomach, thymus, thyroid with parathyroids, tongue, trachea, urinary bladder, uterus with cervix, vagina.
Femoral bone marrow smears were taken from all animals.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No animals died during the study. Blue staining of the coat or tail was observed in one male and one female receiving 200 mg/kg bw/day and in all animals receiving 1000 mg/kg bw/day. Blue staining of the dorsal coat occured predominantly in week 2 for affected high dosage males and in week 3 and 4 for affected high dosage females. Since this sign was not evident at the end of the treatment period its recovery could not be established. Staining of the tail first became evident during week 3 and persisted throughout the reversibility period in most animals.
There were no other signs of a reaction to treatment. There were a few incidences of salivation in association with the dosing procedure but these were either in control or low dose animals and were not attributed to treatment.
The blue staining is related to the blue colour of the pigment. It stained the feces blue and from there, secondary staining of coat and tail occurred. It is not an adverse finding.
BODY WEIGHT AND WEIGHT GAIN
The bodyweight gains of control and treated animals were essentially the same during the treatment period (see table 1) and the revsersibility phase. The slightly lower gain during the treatment period in females receiving 200 mg/kg bw/day and during the reversibility period in femals previously treated at 1000 mg/kg bw/day were considered to represent normal biological variation.
FOOD CONSUMPTION AND FOOD EFFICIENCY
The food consumption of control and treated animals was similar throughout the treatment period and reversibility phase. The food conversion efficiency of control and treated animals was essentially the same during the treatment period and the reversibility phase.
HAEMATOLOGY
Haematological investigations on day 30 of treatment showed no inter-group differences between control and treated animals that could be attributed to treatment. Inter-group differences that attained statistical significance (p<0.05) lacked dosage relationship, were minor or were confined to one sex and therefore considered to be of no toxicological significance.
CLINICAL CHEMISTRY
For mean plasma alanine amino-transferase activities, these were slightly high for females receiving 1000 mg/kg bw/day and slightly low for males receiving 1000 mg/kg bw/day. Examination of individual values showed that these inter-group differences arose as a result of two slightly high control male values and one slightly high value for a female given 1000 mg/kg bw/day. Consequently, the inter-group differences in plasma alanine aminotransferase activity were not attributed to treatment.
Other inter-group differences that attained statistical significance were either minor, lacked dosage relationship or were confined to one sex, and were therefore not attributed to treatment.
URINALYSIS
The composition of urine on day 30 was unaffected by treatment.
ORGAN WEIGHTS
No adverse effects on organ weights were observed.
GROSS PATHOLOGY
Macroscopic examination after 30 days of treatment revealed abnormal contents of the gastro-intestinal tract in two males and one female that received 1000 mg/kg bw/day. The contents were dark or blue and green. This is caused by the colour of the pigment and merely indicates is presence in the gastrointestinal tract.
There were no other macroscopic findings after 30 days of treatment or after 16 days of reversibility that was attributed to treatment or previous treatment with the test material.
HISTOPATHOLOGY:
There were no findings considered to be related to treatment with the test material.
2 males from the 1000 mg/kg bw/day group as well as one male from the 200 mg/kg bw/day group had dilatation and degeneration of the seminiferous tubules in the testes. This degeneration was, however, unilateral and was accompanied in one case by chronic inflammation of the epididymis. It is thought that these dilatations and degenerations may be associated with a blockage of the ducts distal to the testes and are unrelated to treatment.
Other findings were of the types commonly seen in rats of this age and occured with the expected frequency.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed at the limit dose.
Target system / organ toxicity
- Critical effects observed:
- no
Any other information on results incl. tables
Table 1: Body weights of males and females during the treatment period
GROUP: | 1 (Male) | 2 (Male) | 3 (Male) | 4 (Male) | 1 (Female) | 2 (Female) | 3 (Female) | 4 (Female) | |
WEEK | |||||||||
0 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 142 | 149 | 147 | 144 | 134 | 129 | 132 | 130 | |
S.D. | 4.8 | 3.7 | 7.3 | 6.2 | 6.1 | 6.3 | 2.8 | 8.9 | |
1 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 198 | 210 | 208 | 203 | 166 | 161 | 160 | 159 | |
S.D. | 6.7 | 6.1 | 13.6 | 8.9 | 5.9 | 9.6 | 6.5 | 12.7 | |
2 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 249 | 269 | 261 | 255 | 189 | 184 | 181 | 178 | |
S.D. | 11.5 | 9.7 | 21 | 13.2 | 5.3 | 9.5 | 10.6 | 13 | |
3 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 293 | 314 | 301 | 298 | 209 | 203 | 200 | 201 | |
S.D. | 13.4 | 13.3 | 31.7 | 16.2 | 10.2 | 14 | 10.7 | 15.4 | |
4 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 334 | 354 | 333 | 332 | 226 | 221 | 212 | 216 | |
S.D. | 15 | 19 | 39.4 | 21.8 | 13.1 | 15.4 | 12.9 | 17.2 | |
BW Gain 0-4 | N | 10 | 5 | 5 | 10 | 10 | 5 | 5 | 10 |
MEAN | 192 | 206 | 187 | 188 | 93 | 91 | 81 | 86 | |
S.D. | 11.6 | 17.9 | 35.3 | 20.6 | 13.5 | 15.3 | 12.5 | 10.6 | |
As % of control | 107 | 97 | 98 | 98 | 87 | 92 |
Table 2: Liver weights of males and females
Dose group | control | 40 | 200 | 1000 | 0 (recovery) | 1000 (recovery) |
male | 16.7 | 15.4 | 15.8 | 15.6 | 20.6 | 19.8 |
SD | 2 | 0.8 | 2.7 | 1.6 | 1.6 | 2.2 |
female | 9.3 | 9.2 | 9.6 | 10.1 | 11 | 9.2 |
SD | 0.8 | 1 | 0.8 | 0.5 | 1.2 | 1.2 |
Applicant's summary and conclusion
- Conclusions:
- Treatment of rats by gavage for 28 days did not cause treatment-related effects at the limit dose.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Aunque la ECHA ofrece una gran cantidad de material en su idioma, una parte de esta página está solo disponible en inglés. Más información sobre la política de multilingüismo de la ECHA.
Bienvenido a la página web de la ECHA. Este sitio no es plenamente compatible con Explorer 7 (y versiones anteriores). Por favor, actualice su Internet Explorer a una versión más reciente.
Esta web utiliza cookies para mejorar su experiencia de navegación en nuestros sitios web.
Más información sobre el uso de cookies.